Enlaza Therapeutics is a biotechnology company pioneering covalent biologics: a new class of protein-based medicines designed to treat cancer and other serious diseases. Its proprietary War-Lock platform uses synthetic biology and specially engineered amino acids to help therapeutic proteins form an irreversible bond with disease-related targets. The technology is designed to keep medicines inactive while circulating and activate their covalent chemistry only when they engage a specific target.

Unlike conventional protein therapeutics, which bind reversibly and may require prolonged or continuous dosing, Enlaza’s approach aims to sustain target occupancy and therapeutic effects with less systemic exposure. The company says this could improve efficacy while limiting effects on healthy tissues. Its platform is intended to work across a range of protein-drug formats while preserving target specificity and drug-like properties.

Enlaza is developing War-Lock biologics for cancer and other serious conditions, with the broader goal of expanding what protein therapeutics can achieve. The company is led by an experienced biopharmaceutical team with expertise in drug discovery, biologics development, operations, and business development.